TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06184503: A Real-world Analysis of Pharmacodynamic Response to Velmanase Alfa (Lamzede®) Treatment in Patients With Alpha-Mannosidosis Less Than 3 Years of Age

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,905,600

Rescue Site Savings

+$4,548,400

Unlock Full NCT06184503 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06184503 Rescue Dossier →